IBDEI0YS ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17280,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,17281,0)
 ;;=200.80^^111^1078^31
 ;;^UTILITY(U,$J,358.3,17281,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17281,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,17281,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,17281,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,17282,0)
 ;;=201.00^^111^1078^9
 ;;^UTILITY(U,$J,358.3,17282,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17282,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,17282,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,17282,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,17283,0)
 ;;=201.10^^111^1078^10
 ;;^UTILITY(U,$J,358.3,17283,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17283,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,17283,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,17283,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,17284,0)
 ;;=201.20^^111^1078^12
 ;;^UTILITY(U,$J,358.3,17284,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17284,1,1,0)
 ;;=1^201.20
 ;;^UTILITY(U,$J,358.3,17284,1,8,0)
 ;;=8^Hodgkin's Sarcoma
 ;;^UTILITY(U,$J,358.3,17284,2)
 ;;=^265560
 ;;^UTILITY(U,$J,358.3,17285,0)
 ;;=201.40^^111^1078^15
 ;;^UTILITY(U,$J,358.3,17285,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17285,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,17285,1,8,0)
 ;;=8^Lymphocytic-Histiocytic
 ;;^UTILITY(U,$J,358.3,17285,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,17286,0)
 ;;=201.50^^111^1078^30
 ;;^UTILITY(U,$J,358.3,17286,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17286,1,1,0)
 ;;=1^201.50
 ;;^UTILITY(U,$J,358.3,17286,1,8,0)
 ;;=8^Nodular Sclerosis
 ;;^UTILITY(U,$J,358.3,17286,2)
 ;;=^265555
 ;;^UTILITY(U,$J,358.3,17287,0)
 ;;=201.60^^111^1078^24
 ;;^UTILITY(U,$J,358.3,17287,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17287,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,17287,1,8,0)
 ;;=8^Mixed Cellularity
 ;;^UTILITY(U,$J,358.3,17287,2)
 ;;=^265551
 ;;^UTILITY(U,$J,358.3,17288,0)
 ;;=201.70^^111^1078^14
 ;;^UTILITY(U,$J,358.3,17288,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17288,1,1,0)
 ;;=1^201.70
 ;;^UTILITY(U,$J,358.3,17288,1,8,0)
 ;;=8^Lymphocytic Depletion
 ;;^UTILITY(U,$J,358.3,17288,2)
 ;;=^265553
 ;;^UTILITY(U,$J,358.3,17289,0)
 ;;=203.02^^111^1078^26
 ;;^UTILITY(U,$J,358.3,17289,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17289,1,1,0)
 ;;=1^203.02
 ;;^UTILITY(U,$J,358.3,17289,1,8,0)
 ;;=8^Multiple Myeloma in Relapse
 ;;^UTILITY(U,$J,358.3,17289,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,17290,0)
 ;;=204.02^^111^1078^2
 ;;^UTILITY(U,$J,358.3,17290,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17290,1,1,0)
 ;;=1^204.02
 ;;^UTILITY(U,$J,358.3,17290,1,8,0)
 ;;=8^ALL,in Relapse
 ;;^UTILITY(U,$J,358.3,17290,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,17291,0)
 ;;=204.12^^111^1078^6
 ;;^UTILITY(U,$J,358.3,17291,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17291,1,1,0)
 ;;=1^204.12
 ;;^UTILITY(U,$J,358.3,17291,1,8,0)
 ;;=8^CLL,in Relapse
 ;;^UTILITY(U,$J,358.3,17291,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,17292,0)
 ;;=156.2^^111^1079^1
 ;;^UTILITY(U,$J,358.3,17292,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17292,1,1,0)
 ;;=1^156.2
 ;;^UTILITY(U,$J,358.3,17292,1,8,0)
 ;;=8^Malig Neo Ampulla of Vater
 ;;^UTILITY(U,$J,358.3,17292,2)
 ;;=^267100
 ;;^UTILITY(U,$J,358.3,17293,0)
 ;;=154.3^^111^1079^2
 ;;^UTILITY(U,$J,358.3,17293,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17293,1,1,0)
 ;;=1^154.3
 ;;^UTILITY(U,$J,358.3,17293,1,8,0)
 ;;=8^Malig Neo Anus
 ;;^UTILITY(U,$J,358.3,17293,2)
 ;;=^267092
 ;;^UTILITY(U,$J,358.3,17294,0)
 ;;=156.1^^111^1079^3
 ;;^UTILITY(U,$J,358.3,17294,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17294,1,1,0)
 ;;=1^156.1
